Postoperative adjuvant mediastinal radiation in lung cancer.
Postoperative adjuvant mediastinal radiation therapy was used in a group of 18 patients with advanced (nine Stage 2, nine Stage 3) non-small cell carcinoma of the lung who had undergone curative resection. All patients had metastases to hilar and/or mediastinal nodes. The disease-free survival at 2 1/2 years was 55% for Stage 2 patients, suggesting a survival advantage compared to historical controls. No benefit was found in Stage 3 patients. A prospective randomized study of adjuvant radiation in node-positive patients is indicated.
D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D008297:Male; D008479:Mediastinal Neoplasms / Q000517:prevention & control* / Q000556:secondary; D008482:Mediastinum / Q000528:radiation effects*; D008875:Middle Aged; D011184:Postoperative Period